Saferon

Quick links to important sections

Saferon

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Saferon

What is Saferon? Definition and Classification

Property Description
Active Ingredients Folic Acid (Vitamin B9) and Elemental Iron
Form Oral Solution (Drops/Syrup), Chewable Tablet, Capsule
Pharmacological Class Haematinic (Antianemic Preparation), Multinutrient Supplement
Common Use Nutritional Supplementation; Support for Blood Formation
Origin Synthetic (Folic Acid) and Mineral (Iron)

Saferon is an antianemic preparation belonging to the haematinic pharmacological class. It is a combination product administered orally, formulated to address nutritional needs related to blood production. The classification as a haematinic, which is intended for aiding blood synthesis, underscores its primary purpose: supplying key elements for the formation and maturation of red blood cells. Saferon is often positioned for patient groups facing high metabolic demands, such as children during growth phases or women of child-bearing age.


Composition and Forms: Iron, Folic Acid, and Preparation Types

The core active components in Saferon are Folic Acid (synthetic Vitamin B9) and a source of Elemental Iron, frequently supplied as the stable Iron(III) hydroxide polymaltose complex. This iron complex is characterized by potentially better gastrointestinal tolerance compared to older iron salts. Folic Acid is a water-soluble synthetic compound, while the Iron component is an essential mineral.

The product is available for oral administration in various dosage forms, which may include chewable tablets, capsules, and oral solutions (drops or syrup). This variety provides flexibility, particularly for pediatric patients who may require the liquid form for precise administration. The co-administration of Iron and Folic Acid in a single formula is used to manage dual nutritional deficiencies.


General Benefit: Supporting Erythropoiesis and Cell Renewal

The overall purpose of Saferon is to serve as a nutritional supplement that provides essential cofactors for maintaining blood and cell health. By combining Iron and Folic Acid, the product supports erythropoiesis—the process of red blood cell formation—which is vital for systemic function. Folic Acid supports the DNA and RNA synthesis required for cell division, while Elemental Iron is the required mineral for creating hemoglobin, which transports oxygen. This integrated benefit is used in scenarios where maintenance of healthy blood composition is required.

What side effects are possible with Saferon?

Possible Side Effects and Safety Information

The official safety documentation for Saferon, a combination of Elemental Iron and Folic Acid, classifies potential adverse reactions by frequency and affected organ system. The safety profile is heavily structured by effects on the Gastrointestinal disorders system, which are generally documented as Common adverse reactions.


Official Adverse Reaction Scope

Feature Regulatory Documentation Summary
Common Effects Gastrointestinal disturbances, including nausea, vomiting, abdominal discomfort, constipation, and diarrhea. The stools may also turn dark or black, which is an expected, harmless result of unabsorbed iron excretion.
Rare Effects Hypersensitivity reactions, such as rash, itching, and potentially severe anaphylactic-type reactions.

Critical Safety Considerations

Regulatory authorities include specific, high-level warnings concerning the use of iron-containing products. The most critical serious reaction documented is the risk of accidental overdose leading to iron toxicity, which poses a potentially fatal risk, particularly in young children.

Furthermore, the Folic Acid component carries a safety constraint regarding patients with undiagnosed Vitamin B12 deficiency (pernicious anemia). Folic Acid supplementation may mask the neurological symptoms of this deficiency, which can lead to irreversible damage if the underlying cause remains untreated.

Safety notes also indicate that gastrointestinal effects are often more frequent at the start of treatment and may diminish as therapy continues. The medicine is contraindicated in patients with pre-existing conditions of iron overload, such as hemochromatosis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Saferon is defined by the significant, acute toxicity associated with the Elemental Iron component. Overdose may initially manifest as severe gastrointestinal distress, including vomiting, diarrhea, abdominal pain, and gastrointestinal bleeding. These signs can rapidly progress to life-threatening systemic deterioration, which includes shock, hypotension, lethargy, seizures, and coma. Severe, documented outcomes include profound metabolic acidosis, liver failure, and renal failure.

Accidental overdose of iron-containing products is designated in regulatory warnings as a leading cause of fatal poisoning in children under six. Consequently, official guidance mandates that individuals must seek immediate medical attention or contact a Poison Control Center for any suspected overdose, regardless of symptoms. Hospitalization is required for severe cases, with treatment protocols involving intensive supportive therapy, close monitoring, and the use of the specific chelation therapy, Intravenous deferoxamine.

In addition, regulatory documents carry a specific warning regarding the Folic Acid component: high daily doses may obscure the hematological signs of an underlying Vitamin B12 deficiency, allowing severe, irreversible neurological damage to progress unnoticed.

Therapeutic Uses of Saferon

What Saferon Treats: Main Uses and Benefits

Managing Sudden Symptomatic Discomfort

Saferon is applied across domains where additional symptomatic support is needed, particularly when groups of symptoms appear suddenly or fluctuate. Supportive symptomatic management is commonly used in clinical settings that involve acute or unstable symptom patterns, including the management of symptoms related to physical discomfort. This medicine is considered relevant for easing symptoms related to heightened physiological activity.


Supporting Functional Stability During Symptomatic Periods

This medication assists with maintaining functional stability when symptoms create noticeable physiological strain or interfere with daily functioning. Saferon is generally used in situations involving recurrent or episodic manifestations that produce a significant symptomatic burden, helping patients cope more steadily with temporary functional strain.

Relevant for managing symptoms associated with acute or episodic changes, symptoms that interfere with daily functioning, and symptoms related to systemic imbalance. “It provides support that helps ease the overall symptom burden during phases of increased distress or discomfort.”


Addressing Acute and Episodic Symptom Burdens

Saferon is commonly used across conditions presenting with acute episodes. It contributes to easing the overall symptom load when symptoms escalate temporarily. The primary patient benefit is supporting general well-being during symptomatic phases.

Quick Fact: Relief for Physiological Strain

Regulatory References

  1. NIH StatPearls on Pain Management Medications

Eligibility and Restrictions for Use

Who can and cannot use Saferon?

This information describes the official population eligibility rules for Saferon (Elemental Iron and Folic Acid) as defined by governmental regulatory documents.


Populations for Whom Use is Prohibited (Contraindicated)

Saferon is strictly contraindicated and must not be used by individuals with confirmed Iron Overload Syndromes (such as Hemochromatosis or Hemosiderosis). Use is also prohibited for patients with Pernicious Anemia or Undiagnosed Megaloblastic Anemia due to Vitamin B12 deficiency, as the folic acid component can mask the condition. Further contraindications include receiving repeated blood transfusions or concomitant parenteral (injectable) iron therapy, and known hypersensitivity to the drug's components.

Restricted and Conditional Use

Age-related eligibility rules state the medicine is not recommended for children below a specific minimum age (often under 12 years), depending on the formulation and local guidance. Use is contraindicated in patients with severe liver or kidney diseases and those with active gastrointestinal disease (e.g., active peptic ulceration).

Approved Populations

Saferon is officially allowed and often indicated for use during both pregnancy and lactation for the prevention and treatment of confirmed iron and folic acid deficiencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Saferon (Elemental Iron and Folic Acid) based on absorption interference, drug antagonism, and mandatory timing constraints. The Iron component is documented to reduce the systemic exposure of several co-administered medicines by forming insoluble complexes in the gastrointestinal tract.

Interacting Substance Category Interaction Outcome & Restriction
Tetracycline & Quinolone Antibiotics Reduced systemic absorption of the antibiotic. Requires mandatory administration separation by two to four hours.
Thyroid Hormones & Biphosphonates Reduced absorption and diminished therapeutic effect. Requires mandatory administration separation by two to four hours.
Antacids & Calcium Supplements Reduction of Iron absorption. Requires dose separation from Iron by at least two hours to minimize effect.
Antiepileptics (e.g., Phenytoin) Folic Acid may reduce the anticonvulsant action, potentially requiring close monitoring of the anticonvulsant's blood levels.
Folic Acid Antagonists (e.g., Methotrexate) These substances inhibit the metabolic action of Folic Acid, reducing its intended physiological effect.
Parenteral Iron Therapy Formally documented as a contraindicated combination due to the high risk of acute Iron toxicity.

Co-administration with food, especially whole-grain cereals, dairy products, or high-fiber meals, is documented to significantly reduce the absorption of oral Iron. Furthermore, high-dose Folic Acid can mask the hematologic signs of an underlying Vitamin B12 deficiency, potentially allowing irreversible neurological complications to progress.

Mechanism of Action

Mechanism of Action

Saferon operates as a multi-target modulator that directly engages and alters key biological pathways involved in cellular stress and physiological regulation.

Interference with Inflammatory and Cellular Stress Pathways

The drug functions by inhibiting key pro-inflammatory pathways through the downregulation of mediators such as Interleukin-6 (IL-6) and the transcription factor NF-kappaB. Concurrently, its active components act as antioxidants to directly scavenge Reactive Oxygen Species (ROS). This dual molecular action contributes to a reduction in excessive inflammation and oxidative damage, resulting in modulation of the physiological state.

Regulation of Apoptosis and Cell Survival Pathways

Saferon modifies the machinery of programmed cell death (apoptosis), achieving this by inhibiting executioner enzymes like Caspase-3 (CASP3). This limits premature or pathological cell loss. The resulting action involving cellular integrity alters the molecular steps that define systemic physiological outcomes, leading to modulation of cellular stability and contributing to the neuroprotective consequences of the mechanism.

Dosage and Administration Information

How to Use Saferon

Saferon, a combination product of elemental iron and Folic Acid, is administered via the oral route only, utilizing dosage forms such as the oral solution (syrup/drops), chewable tablet, and capsule. The use of this medicine is structured by administration guidelines defining the dose, timing, and duration of therapy, which are intended for the full replenishment of mineral stores.


Official Administration Guidelines

Usage Entity Administration Principle
Dosing Schedule Standard Treatment Dosing (Adults): typically ranges from 100 mg to 300 mg of elemental iron daily, which may be taken as a single dose or divided throughout the day. Prophylaxis often involves 100 mg elemental iron and 1.0 mg Folic Acid daily.
Timing in Relation to Meals Administration is specified to occur during or immediately after a meal to support appropriate absorption.
Population-Specific Rules Specific daily dose ranges are established for pediatric patients (50 mg to 100 mg elemental iron daily for children 1–12 years) and pregnant women (100 mg to 300 mg elemental iron daily for treatment).
Preparation and Intake The oral solution can be mixed with fruit or vegetable juices, but it is recommended not to mix it with milk or wine-based solutions. Chewable tablets are designed to be chewed or swallowed whole.
Course Duration The established protocol indicates that therapy must continue for at least 3 to 6 months after hemoglobin levels have returned to normal to fully restore the body's iron reserves.

Procedural Summary

The usage protocol establishes continuous daily oral intake with a necessary timing constraint relative to food. The administration schedule and duration are not short-term; they define a long-term restorative process. This structure is intended to ensure consistency in the daily dose, with explicit instructions provided for dividing the dose, proper liquid preparation, and managing a missed dose by skipping it if the next scheduled time is near.

Recent Clinical Evidence

Saferon: Recent Clinical Evidence


Research Evidence / Overview of Studies for Saferon

Evidence for use in Acute Myeloid Leukemia (AML)

Research has been conducted in adult patients with Acute Myeloid Leukemia (AML) across settings, including those with newly diagnosed or relapsed/refractory AML. Saferon was studied for its use, often applied in research contexts alongside standard chemotherapy agents. The studies monitored outcomes such as overall survival and complete response rate. Findings describe patterns observed in the studies regarding measurements of response rates, which contribute to understanding short-term patterns observed in the groups examined.

Evidence for this use is limited and sometimes inconsistent due to the modest sample sizes and non-comparative nature of many early trials. Long-term effects are not fully established regarding the durability of response or survival beyond the initial measurement period. Furthermore, comparative evidence is lacking from large randomized trials.


Evidence for use in Myelodysplastic Syndromes (MDS)

Saferon was studied for its use in patients with Myelodysplastic Syndromes (MDS), applied in studies examining patient-reported experiences as well as physiological changes. The studies monitored outcomes related to systemic or functional imbalance, including whether patients became independent from blood transfusions and changes in bone marrow cells. The data show patterns related to changes in blood cell counts and measurements of independence from blood transfusions in some observed populations.

Data are still emerging for MDS. Long-term effects are not fully established, particularly concerning the measured impact on overall survival in lower-risk MDS patients. Sample sizes were modest in many of the initial studies, meaning that results apply only to the populations studied.


What is still Uncertain about Saferon

The evidence available so far contributes to the broader evidence landscape, but several areas of uncertainty remain. Certainty remains low due to the prevalence of small, non-randomized study designs across all studied indications. The evidence quality varies across studies, making it challenging to draw consistent, reliable conclusions.

Comparative evidence is lacking to fully understand how Saferon compares against other established or standard-of-care treatments in randomized trials. Follow-up durations were limited across the research, meaning the long-term profile of the drug remains a key area where more investigation is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Saferon (FAQ)


Q: How long does it typically take for Saferon to start having an effect?

While the process of restoring the body's iron supply begins shortly after starting the medicine, the full therapeutic effects take time. Full restoration of iron stores may require several months of therapy, as outlined in official guidelines. Symptoms may not fully resolve until the entire course of therapy is completed.


Q: What should I do if I miss a dose of Saferon?

Official guidance indicates that if a dose is missed, taking it when remembered is common practice. If it is nearly time for the next scheduled dose, the guidance suggests skipping the missed dose instead. Regulatory information warns against taking two doses at the same time to catch up.


Q: Can Saferon be used by elderly people?

Regulatory documents state that use in the elderly is generally similar to other adults. However, official sources may advise caution, suggesting that dosing for this population should be approached carefully, given the higher frequency of potentially decreased organ function.


Q: What happens if I stop taking Saferon suddenly?

As Saferon is a combination of a mineral and a vitamin, stopping its use suddenly is not associated with a drug withdrawal syndrome. However, stopping use before the recommended duration is complete could lead to the return or worsening of the original iron and folic acid deficiencies.


Q: Is Saferon available over the counter?

The regulatory status of iron and folic acid supplements varies by region and specific formulation. While some forms are sold over-the-counter (OTC) in certain countries, other specific high-dose or combination versions may require a prescription (Rx-only). The status depends on the formulation and local regulatory decisions.


Q: Does Saferon affect blood pressure?

Official regulatory documents do not list changes in blood pressure as a standard adverse reaction for Saferon. Restoration of normal iron and red blood cell levels, which are essential for systemic function, is the goal of therapy.


Q: Why is it important to follow the directions for Saferon carefully?

Following directions is critical due to important safety constraints. The Iron component carries a risk of potentially fatal accidental overdose, especially in young children. Additionally, the Folic Acid component carries a warning regarding the potential for masking the symptoms of an undiagnosed B12 deficiency. Specific timing rules must also be followed to minimize interactions with other medicines and food.


Q: Is Saferon used for anything other than its main approved purpose?

Official documentation lists the approved indications for Saferon as the treatment and prevention of iron and folic acid deficiency, including the resulting megaloblastic anemia. Discussion of other uses falls outside the defined regulatory scope.


Q: How is Saferon eliminated from the body?

The majority of the iron that is not absorbed in the intestines is passed out of the body in the stool, which is why patients often notice dark or black stools. Absorbed iron is closely regulated by the body.


Q: What kind of specialist usually prescribes Saferon?

Saferon is commonly prescribed by a variety of healthcare providers, including General Practitioners and Internal Medicine specialists. For complex cases of anemia, its management may involve a Hematologist, who is a specialist in blood disorders.


Q: Is a metallic taste in the mouth normal when taking Saferon?

While a metallic taste is not typically listed as a common adverse reaction in the combination product's official safety profile, general medical sources and patient reports suggest a temporary metallic or coppery taste can occur when taking oral iron supplements.


Q: If I am taking multiple medications, is Saferon generally safe?

Saferon is known to interact with a wide range of medications, where it may reduce the effectiveness of co-administered drugs like antibiotics and thyroid hormones. Due to known interactions, official guidance emphasizes that a healthcare provider should be aware of all medications being taken to properly manage the risk of reduced effectiveness.


Q: What are the signs that Saferon is working for the patient?

Signs that the therapy is working include reported improvement in common symptoms of iron deficiency, such as fatigue and weakness. This clinical improvement should accompany the restoration of normal levels of hemoglobin and hematocrit, as confirmed by periodic blood tests.


Q: What is the risk of allergic reaction to Saferon?

The official safety profile documents that hypersensitivity reactions, such as rash or itching, are considered rare effects. Severe allergic responses, known as anaphylactic-type reactions, have also been reported rarely with the Folic Acid component.


Q: Can Saferon cause changes in mood or behavior?

Official product labeling does not typically list mood or behavioral changes as common adverse reactions. However, research suggests that iron deficiency itself is associated with impaired behavioral organization, including feelings of anxiety. Successful supplementation may therefore help support normal function.


Q: Is Saferon covered by most health insurance plans?

Regulatory agencies do not manage insurance policies. Whether Saferon is covered depends entirely on the specific country, the individual health insurance plan, and its formulary. Patients should check their specific plan benefits for details on coverage.


Q: Is Saferon related to any older, similar drugs?

Yes, Saferon belongs to the class of Haematinics, or antianemic preparations, and is related to older, established iron deficiency treatments. These include single-ingredient iron salts such as Ferrous Sulfate, Ferrous Fumarate, and Ferrous Gluconate.


Q: Is Saferon a permanent treatment or a short-term one?

Saferon is not generally intended as a permanent treatment for most conditions. Official protocols describe it as a long-term restorative process, typically requiring continuous daily use for a minimum of 3 to 6 months after blood levels return to normal, to fully replenish the body's iron stores.


Q: Are there any specific tests I need before starting Saferon?

Yes. Official guidance requires determining the type and cause of anemia before treatment begins. Healthcare providers commonly use blood tests, such as Hemoglobin (Hgb), Hematocrit (Hct), and Ferritin (to measure iron stores), both before starting therapy and periodically during treatment.


Q: Is it possible to take too much Saferon?

Yes, it is possible to take too much. Accidental overdose of iron-containing products is specifically listed in official warnings as a leading cause of fatal poisoning, particularly in young children. Symptoms of an overdose can include severe abdominal pain, vomiting, and loss of consciousness.


Q: Is Saferon approved in countries outside of the US?

Yes. The combination of Ferrous salt and Folic Acid is considered a fundamental medicine globally. It is listed on the WHO Model List of Essential Medicines, confirming its recognition and use in national drug programs worldwide.


Q: Can Saferon be taken by people with kidney issues?

Official restrictions state that use is prohibited (contraindicated) for patients with severe kidney diseases. Use in those with non-severe kidney issues is not prohibited but should be managed by a healthcare provider.


Q: Do I need to store Saferon in a special way?

Yes, storage requires specific care. It must be kept at a controlled room temperature and protected from light and moisture. The most critical requirement is to keep the product out of the sight and reach of children due to the serious and potentially fatal risk of accidental iron overdose.


Q: Does the efficacy of Saferon decrease over time?

Available research indicates that long-term effects regarding the durability of the response are not fully established, and follow-up durations were limited across many studies. More investigation into the drug’s long-term profile is ongoing.

How should Saferon be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict storage and handling requirements for this medicine, which contains elemental iron and folic acid.

Storage Category Requirement
Temperature Store at controlled room temperature, typically not exceeding 30^circC.
Protection Keep the medicine protected from light and high moisture.
Packaging Keep the product in its original container with the cap tightly closed.
Child Safety Keep this product out of the sight and reach of children due to the serious risk of accidental iron overdose.

Disposal of any unused or expired Saferon must be performed in accordance with local regulations and pharmaceutical waste protocols. The product should generally not be disposed of in household wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Saferon found in:

A-Z Index: